Skip to main content
Open access
Article
Published Online: 5 June 2017

Persistent and Long-Term Neuropsychiatric Implications of Cannabis Use in Adolescents

Publication: American Journal of Psychiatry Residents' Journal
As society grapples with questions regarding the legality and safety of cannabis, it is particularly important to consider epidemiological trends and the implications of cannabis use in younger populations. A remarkable 78% of first-time users are between the ages of 12 and 20 years old (1). The annual U.S. Monitoring the Future Survey demonstrates an ongoing, significant decrease in perceived risk that high school students attribute to cannabis use (2). Further evidence suggests that patterns of substance abuse are highly correlated with perceptions of risk (3). The adverse effects of acute cannabis intoxication vary among users but are well-characterized by responses such as impaired short-term memory, impaired motor coordination, altered judgment, paranoia, and psychosis at higher doses (4). The persistent and long-term neuropsychiatric consequences of cannabis use in humans have proven more challenging to investigate, but there is a growing body of recent scientific literature that addresses these concerns. It is noteworthy that the potency of recreationally available strains has also climbed significantly over time (5). The purpose of the present article was to examine the basis for increased adolescent vulnerability to chronic effects of cannabis use, specifically in the domains of cognition, psychosis, and addiction.

Basis for Heightened Vulnerability

Brain development and maturation processes begin in utero and continue significantly through the early decades of life (see reference 6 for a review). Component processes include neuronal migration and differentiation, synaptogenesis, axon formation, dendritic proliferation, myelination, pruning, apoptosis, and other changes, all potentially at risk of disruption with early-onset cannabis use. The effects of delta 9-tetrahydrocannabinol (THC), the major psychoactive constituent of cannabis, are known to be mediated by activity at cannabinoid receptors located in the CNS. Cannabinoid receptors mature in adolescence (7) and are highly distributed in critical brain regions such as the prefrontal cortex, anterior cingulate cortex, basal ganglia, hippocampus, amygdala, and cerebellum (8). Various endogenous cannabinoids have been identified as ligands with innate cannabinoid receptor activity, and numerous animal studies suggest that this endocannabinoid system is involved in the regulation of key neurodevelopmental processes that occur through adolescence and may be disrupted by exogenously administered cannabinoids (9). Moreover, neuroimaging studies comparing the brains of adolescent chronic cannabis users and healthy control subjects point to structural and functional alterations that are apparent soon after initiation of drug use and persist even after months of abstinence (10). These studies do not necessarily indicate causation; however, the negative effects of cannabis on functional connectivity in adults are more notable if use begins at young ages (11). Taken together, this evidence makes a strong case for concern over adolescent cannabis use.

Cognition

Impaired verbal learning and memory have been consistently observed in chronic cannabis users in cross-sectional studies, including adolescent populations (1214). Evidence for working memory impairment has been mixed, but studies have also differed in the specific tasks employed and in subjects’ history of cannabis use. There is strong and largely consistent evidence for attention deficits associated with chronic cannabis exposure in adolescents (see reference 15 for a review). Prior cannabis use appears to impair executive function in an age-dependent, dose-responsive manner, and adolescent-onset cannabis users demonstrate more severe and persistent cognitive impairment than adult-onset users (9, 1619). Whether there is recovery of impairment with prolonged abstinence remains a topic of debate (see reference 15 for a review).
Prolonged, heavy cannabis use has been associated with an amotivational state (2022), which may predict impaired learning and educational underachievement. A well-known study by Meier et al. (19) observed a longitudinal 8-point decline in IQ among heavy, adolescent-onset cannabis users, which was not restored by cessation. However, these findings have been challenged due to the possibility of other confounding variables in repeat analyses (23). An analysis of two longitudinal twin sibling studies also did not find a significant IQ decline between frequently using and non-using twins, where frequent cannabis use was defined as 30 or more times of lifetime use (24).

Psychosis

Psychosis outcomes in relation to cannabis use are at times poorly defined, but Ranganathan et al. (25) argues for characterization based on timing, duration, and resolution. Within this framework, cannabinoids have been associated with acute-onset psychosis through intoxication that resolves without clinical intervention, acute-onset psychosis that persists beyond intoxication and requires clinical intervention, and chronic psychotic disorders that emerge later in life, also requiring intervention. A review by Radhakrishnan et al. (6) concluded that the connection between cannabis and varieties of psychosis meets many but not all of the criteria for causality, passing measures such as the existence of a temporal relationship between cannabis use and psychosis, a dose-responsive effect, biological and experimental plausibility, and consistency in findings. However, a causal relationship has been questioned due to an absence of specificity and strength of association. Other factors may also play an important role; for example, variants of the AKT1 and COMT genes, which are involved in dopamine signaling and metabolism, have been proposed as significant moderators of the risk of psychotic disorder with adolescent cannabis exposure (26, 27). These findings ultimately point to significantly greater risk of psychosis associated with adolescent-onset use. Another epidemiological review by Gage et al. (28) proposes that while it is challenging to establish causality without further evidence, the significant cannabis-psychosis relationship still merits attention and public health action.

Addiction

Around 30% of all cannabis users may develop some degree of problem use, which can lead to dependence, and in severe cases takes the form of addiction (29). There is laboratory evidence of tolerance to the effects of THC (30) and clinical evidence of a withdrawal syndrome—commonly characterized by symptoms such as anger, aggression, irritability, anxiety, decreased appetite or weight loss, and sleep difficulties—that complicates abstinence in users trying to quit (31). Theories of addiction suggest that repeated drug use disrupts prefrontal cortex function and results in behavioral changes that contribute to problem use, specifically in areas of emotional regulation, inhibitory control, salience attribution, maintenance of motivational arousal, and self-awareness (32). Moreover, epidemiological studies report an age-dependent, dose-response relationship between prior cannabis use, impaired executive control (16), and development of cannabis use disorder (3335). In perspective, individuals who use cannabis before the age of 18 are four to seven times more likely than adults to develop problem use (36). Among cannabis-related admissions to substance abuse treatment facilities in the United States, 81% of use was initiated by age 16 (37).

Conclusions

While we are still in the early stages of understanding the effects of cannabis on the developing brain, there is a growing body of scientific literature that supports various long-term consequences of adolescent-onset cannabis use relating to cognitive impairment, psychosis, and addiction. Rather than thinking of these deficits as unique outcomes, it may be useful to consider such dysfunction as a shared product of disrupted neurodevelopment, and early impairments in cognition may very well underlie manifestations of psychosis and patterns of problematic drug use that characterize addiction. Still, much of the existing evidence is based on observational studies that are ultimately limited in generalizability. Going forward, it will be important to build on converging evidence across disciplines to better characterize the relationship between cannabis and chronic neuropsychiatric outcomes. Furthermore, a greater understanding of moderating variables and risk factors will be paramount to guiding effective public health efforts. Finally, it is unclear to what extent the public is aware of the implications of adolescent cannabis use. An accurate and informed opinion of cannabis must be a part of the emerging conversation on recreational consumption and effective drug policy.

Key Points/Clinical Pearls

Cannabis use is significant in adolescent populations, although the persistent and long-term neuropsychiatric consequences of early use are not well understood.
There is evidence for increased vulnerability to the effects of cannabis use in adolescents, due to ongoing brain development and maturation.
Increasing literature supports long-term cognitive impairment, psychosis, and addiction related particularly to adolescent-onset cannabis use.
While further study is needed, current policy and public health efforts should account for our current scientific understanding of these outcomes.

References

1.
SAMHSA: Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings (NSDUH Series H-48, HHS Publication No [SMA] 14-4863). Rockville, Md, Substance Abuse and Mental Health Services Administration, 2014
2.
Johnston LD, O’Malley PM, Bachman JG, et al: Monitoring the Future National Results on Drug Use: 2015 Overview: Key Findings on Adolescent Drug Use. Ann Arbor, Mich, University of Michigan Institute for Social Research, 2016
3.
Pacula RL, Kilmer B, Grossman M, et al: Risks and prices: The role of user sanctions in marijuana markets. B E J Econom Anal Policy 2010; 10(1)
4.
Volkow ND, Baler RD, Comptom WM, et al: Adverse health effects of marijuana use. N Engl J Med 2014; 370(23):2219–2227
5.
El Sohly MA, Mehmedic Z, Foster S, et al: Changes in cannabis potency over the last 2 decades (1995–2014): Analysis of Current Data in the United States. Biol Psychiatry 2016; 79(7):613–619
6.
Radhakrishnan R, Wilkinson ST, D’Souza DC: Gone to pot: A review of the association between cannabis and psychosis. Front Psychiatry 2014; 5(54)
7.
Belue RC, Howlett AC, Westlake TM, et al: The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. Neurotoxicol Teratol 1995; 17:25–30
8.
Burns HD, Van LK, Sanabria-Bohorquez S, et al: [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci USA 2007; 104(23):9800–9805
9.
Lubman DI, Cheetham A, Yücel M: Cannabis and adolescent brain development. Pharmacol Ther 2015; 148:1–16
10.
Batalla A, Bhattacharyya S, Yucel M, et al: Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PloS One 2013; 8:e55821
11.
Zalesky A, Solowij N, Yücel M, et al: Effect of long-term cannabis use on axonal fibre connectivity. Brain 2012; 135:2245–2255
12.
Dougherty DM, Mathias CW, Dawes MA, et al: Impulsivity, attention, memory, and decision: making among adolescent marijuana users. Psychopharmacology (Berl) 2013; 226:307–319
13.
Harvey MA, Sellman JD, Porter RJ, et al: The relationship between non-acute adolescent cannabis use and cognition. Drug Alcohol Rev 2007; 26:309–319
14.
Solowij N, Jones KA, Rozman ME, et al: Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacology (Berl) 2011; 216:131–144
15.
Broyd SJ, van Hell HH, Beale C, et al: Acute and chronic effects of cannabinoids on human cognition: A systematic review. Biol Psychiatry 2016; 79(7):557–567
16.
Ehrenreich H, Rinn T, Kunert HJ, et al: Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl) 1999; 142(3):295–301
17.
Tait RJ, Mackinnon A, Christensen H: Cannabis use and cognitive function: 8-year trajectory in a young adult cohort. Addiction 2011; 106(12):2195–2203
18.
Tapert SF, Granholm E, Leedy NG, et al: Substance use and withdrawal: neuropsychological functioning over 8 years in youth. J Int Neuropsychol Soc 2002; 8(7):873–883
19.
Meier MH, Caspi A, Ambler A, et al: Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 2012; 109(40):​2657–​2664
20.
Silins E, Horwood LJ, Patton GC, et al: Cannabis cohorts research consortium: Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry 2014; 1(4):286–293
21.
Paule MG, Allen RR, Bailey JR, et al: Chronic marijuana smoke exposure in the rhesus monkey, II: effects on progressive ratio and conditioned position responding. J Pharmacol Exp Ther 1992; 260(1):210–222
22.
Lane SD, Cherek DR, Pietras CJ, et al: Performance of heavy marijuana-smoking adolescents on a laboratory measure of motivation. Addict Behav 2005; 30(4):​815–​828
23.
Rogeberg O: Correlations between cannabis use and IQ change in the Dunedin cohort are consistent with confounding from socioeconomic status. Proc Natl Acad Sci USA 2013; 110:4251–4254
24.
Jackson NJ, Isen JD, Khoddam R, et al: Impact of adolescent marijuana use on intelligence: Results from two longitudinal twin studies. Proc Natl Acad Sci USA 2016; 113(5):500–508
25.
Ranganathan M, Skosnik PD, D’Souza DC: Marijuana and madness: Associations between cannabinoids and psychosis. Biol Psychiatry 2016; 79(7):511–513
26.
Di Forti M, Iyegbe C, Sallis H, et al: Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 2012; 72(10):811–816
27.
Caspi A, Moffitt TE, Cannon M, et al: Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005; 57(10):1117–1127
28.
Gage SH, Hickman M, Zammit S: Association between cannabis and psychosis: Epidemiological evidence. Biol Psychiatry 2016; 79:549–556
29.
Hasin DS, Saha TD, Kerridge BT, et al: Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry 2015; 72(12):1235–1242
30.
Lichtman A, Martin B: Cannabinoid tolerance and dependence. Handb Exp Pharmacol 2005; 168:691–717
31.
Budney A, Hughes J: The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006; 19:233–238
32.
Goldstein RZ, Volkow ND: Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci 2011; 12(11):652–669
33.
Anthony JC, Warner LA, Kessler RC: Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 1994; 2(3):244–268
34.
Chen C-Y, Storr CL, Anthony JC: Early-onset drug use and risk for drug dependence problems. Addict Behav Rep 2009; 34(3):319–322
35.
Kokkevi A, Nic Gabhainn S, Spyropoulou M, et al: Early initiation of cannabis use: a cross-national European perspective. J Adolesc Health 2006; 39(5):712–719
36.
Winters KC, Lee C-YS: Likelihood of developing an alcohol and cannabis use disorder during youth: Association with recent use and age. Drug Alcohol Depend 2008; 92(1–3):239–247
37.
SAMHSA: National Admissions to Substance Abuse Treatment Services Treatment Episode Data Set (TEDS): 2002–2012 (BHSIS Series S-71, HHS Publication No [SMA] 14-4850). Rockville, Md, Substance Abuse and Mental Health Services Administration, 2014

Information & Authors

Information

Published In

Go to American Journal of Psychiatry Residents' Journal
American Journal of Psychiatry Residents' Journal
Pages: 8 - 10

History

Published in print: June 01, 2017
Published online: 5 June 2017

Authors

Details

David S. Mathai, B.S.
At the time this article was accepted for publication, David Mathai was a fourth-year medical student at Baylor College of Medicine, Houston. He will begin his psychiatry residency on June 26, 2017, at Baylor College of Medicine.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share